Price T Rowe Associates Inc Argenx Se Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in Argenx Se stock. As of the latest transaction made, Price T Rowe Associates Inc holds 5,820,547 shares of ARGX stock, worth $3.67 Billion. This represents 0.36% of its overall portfolio holdings.
Number of Shares
5,820,547
Previous 5,598,563
3.97%
Holding current value
$3.67 Billion
Previous $2.41 Billion
31.05%
% of portfolio
0.36%
Previous 0.29%
Shares
16 transactions
Others Institutions Holding ARGX
# of Institutions
400Shares Held
30.9MCall Options Held
376KPut Options Held
489K-
Artisan Partners Limited Partnership Milwaukee, WI3.51MShares$2.21 Billion2.99% of portfolio
-
Janus Henderson Group PLC London, X02.48MShares$1.56 Billion0.72% of portfolio
-
Capital World Investors Los Angeles, CA1.7MShares$1.07 Billion0.15% of portfolio
-
Avoro Capital Advisors LLC New York, NY1.24MShares$780 Million10.11% of portfolio
-
Black Rock Inc. New York, NY1.01MShares$637 Million0.01% of portfolio
About ARGENX SE
- Ticker ARGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,323,800
- Market Cap $34.9B
- Description
- argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...